Literature DB >> 4195760

Proposed guidelines for protocol studies. II. Plasma cell myeloma. Prepared by a Committee of the Chronic Leukemia--Myeloma Task Force, National Cancer Institute.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 4195760

Source DB:  PubMed          Journal:  Cancer Chemother Rep 3        ISSN： 0069-0139


× No keyword cloud information.
  9 in total

1.  Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents.

Authors:  Carlos Fernández de Larrea; Natalia Tovar; M Teresa Cibeira; Juan I Aróstegui; Laura Rosiñol; Montserrat Elena; Xavier Filella; Jordi Yagüe; Joan Bladé
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

2.  Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.

Authors:  Abdullah S Al Saleh; Harsh V Parmar; Alissa Visram; Eli Muchtar; Francis K Buadi; Ronald S Go; Angela Dispenzieri; Prashant Kapoor; Rahma Warsame; Martha Q Lacy; David Dingli; Nelson Leung; Wilson I Gonsalves; Taxiarchis V Kourelis; Morie A Gertz; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-04-07

3.  Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.

Authors:  M R Cooper; A Fefer; J Thompson; D C Case; R Kempf; R Sacher; J Neefe; J Bickers; J H Scarffe; R J Spiegel
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Authors:  Ticiana B Leal; Scot C Remick; Chris H Takimoto; Ramesh K Ramanathan; Angela Davies; Merrill J Egorin; Anne Hamilton; Patricia A LoRusso; Stephen Shibata; Heinz-Josef Lenz; James Mier; John Sarantopoulos; Sridhar Mani; John J Wright; S Percy Ivy; Rachel Neuwirth; Lisa von Moltke; Karthik Venkatakrishnan; Daniel Mulkerin
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-09       Impact factor: 3.333

5.  Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome.

Authors:  Chrissy H Y van Beurden-Tan; Pieter Sonneveld; Carin A Uyl-de Groot
Journal:  BMC Cancer       Date:  2022-05-30       Impact factor: 4.638

6.  Peptichemio induction therapy in myelomatosis.

Authors:  G Merlini; P G Gobbi; A Riccardi; G Riva; C Sardi; S Perugini
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study.

Authors:  M Eriksson; B Hållberg
Journal:  Cancer Causes Control       Date:  1992-01       Impact factor: 2.506

8.  Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.

Authors:  Heidi Schwarzenbach
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

9.  Multiple myeloma in Korea--clinical analysis and treatment results in 61 cases.

Authors:  H J Kim; D S Heo; Y J Bang; S J Lee; D H Choi; S Y Park; B K Kim; N K Kim; M Heo; M Lee
Journal:  Korean J Intern Med       Date:  1987-01       Impact factor: 2.884
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.